GYKI 53655 hydrochloride

An Antagonist of AMPA and Kainate Receptors
  • New
Cat #: G-220
Sizes: 5 mg, 10 mg, 25 mg, 50 mg
  • Promotion
  • Lyophilized Powder
  • Bioassay Tested
  • Shipped at Room Temp.
  • Source: Synthetic
    MW: 388.85 Da.
    Purity >99%.
    Effective concentration 0.1-100 µM.
    Chemical name 5-(4-aminophenyl)-N,8-dimethyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide;hydrochloride.
    Molecular formula C19H21ClN4O3.
    CAS number 143692-48-2.
    Activity GYKI 53655 hydrochloride, an analogue of GYKI 52466 hydrochloride (#G-125), is a non-competitive antagonist and negative allosteric modulator of AMPA receptors (GluR1 IC50 = 5.9 µM)1, selective over Kainate receptors (GluK3 IC50 = 63 µM)2. Exhibits anticonvulsant and neuroprotective activity both in vitro and in vivo3.
    Storage before reconstitution The product should be stored desiccated at 4°C.
    Reconstitution Soluble up to 100 mM in DMSO or water. Centrifuge all products before handling (10000 x g 5 min).
    Storage after reconstitution

    Up to four weeks at 4°C or three months at -20°C.

    It is recommended to aliquot stock solutions to prevent repeated thawing.

    Our bioassay
    Alomone Labs GYKI 53655 hydrochloride inhibits GluA1 channels expressed in Xenopus oocytes. 
    Representative time course of GluA1 current, activated by a continuous application (top dotted line) of 1 µM (S)-AMPA (#A-267), and reversibly inhibited by 50 µM GYKI 53655 hydrochloride (#G-220), as indicated (bar), at a holding potential of -80 mV.
    1. Chizh, B.A. et al. (1994) Br. J. Pharmacol. 112, 843.
    2. Chizh, B.A. et al. (1994) Br. J. Pharmacol. 112, 843.
    3. Orav, E. et al. (2017) eNeuro 4, 3.
    Target: AMPA, Kainate receptors


    Use code: new-yl30-18
    Valid until January 31st, 2018.

    New website special

    Last update: 25/12/2017

    GYKI 53655 hydrochloride, a racemic 2,3-benzodiazepine is a AMPA and Kainate receptor antagonist. It acts as a non-competitive antagonist and negative allosteric modulator of AMPA receptors and is selective over Kainate receptors. It inhibits AMPA mediated responses in recombinant human GluA1 receptors expressed in HEK293 cells with an approximate IC50 values of 6 µM, and in recombinant human GluA4 expressing cells with an approximate IC50 values of 5 µM1. GYKI 53655 have been reported to be therapeutically effective in several animal models of epilepsy and global brain ischaemia1.

    The ionotropic glutamate AMPA receptors (AMPARs) are the primary receptors that mediate fast excitatory synaptic transmission in the mammalian brain. This function is essential for synaptic plasticity, learning, and memory1,2.

    Kainate receptors are highly expressed in the developing brain, where they are tonically activated to modulate synaptic transmission, network excitability, and synaptogenesis3.

    Alomone Labs is pleased to offer GYKI 53655 hydrochloride (#G-220).

    For research purposes only, not for human use